Analysts Offer Insights on Healthcare Companies: Valneva (GB:0OB3), Sartorius Stedim Biotech (GB:0RG8) and Cryo-Cell International (CCEL)
Valneva Analysis: Analyst Justine Telliez from Kepler Capital maintains a Buy rating for Valneva with a price target of EUR8.10, despite the stock closing at EUR2.66, near its 52-week low; the consensus rating is Moderate Buy with a target of EUR7.30.
Sartorius Stedim Biotech and Cryo-Cell International Ratings: Oliver Reinberg holds a Hold rating for Sartorius Stedim Biotech with a price target of EUR155.00, while Allen Klee reiterates a Buy rating for Cryo-Cell International with a target of $9.00, both reflecting a Moderate Buy consensus in their respective sectors.
Trade with 70% Backtested Accuracy
Analyst Views on CCEL
About CCEL
About the author
Cryo-Cell International Inc Reports Decrease in Q3 Profit
Earnings Decline: Cryo-Cell International Inc reported a decrease in earnings for the third quarter, with profits falling to $0.75 million ($0.09 per share) from $1.05 million ($0.13 per share) in the same period last year.
Revenue Drop: The company's revenue also declined by 3.0%, totaling $7.83 million compared to $8.07 million in the previous year.
Insider Buying Update for Friday, September 12: CCEL, AROW
Cryo-Cell International Insider Activity: Chairman and Co-CEO David Portnoy purchased 42,900 shares of CCEL at $4.43 each, totaling $189,986, and is currently up 6.1% based on recent trading highs.
Arrow Financial Insider Activity: CFO Penko Krassimir Ivanov bought 5,000 shares of AROW at $29.10 each for a total of $145,499, with previous investments totaling $391,248 at an average of $29.14 per share.
Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend
Dividend Announcement: Cryo-Cell International, Inc. has approved a reduced quarterly cash dividend of $0.15 per share due to the current economic environment, with payment expected on May 30, 2025.
Company Overview: Founded in 1989, Cryo-Cell is the first private cord blood bank and has provided services to over 500,000 parents globally, while also partnering with Duke University for public banking initiatives.
Maxim Group Maintains Buy on Cryo-Cell International, Lowers Price Target to $8.5
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
Financial Performance: Cryo-Cell International reported a revenue increase to $32.0 million for fiscal 2024, with a net income of $402,000, contrasting with a net loss of $9.5 million in the previous year due to significant impairments.
Company Overview and Future Outlook: Founded in 1989, Cryo-Cell is a leading private cord blood bank that has expanded its services and partnerships, including a collaboration with Duke University, while anticipating higher legal expenses in fiscal 2025.
Cryo-Cell reports FY24 EPS 5c vs ($1.14) last year
Fiscal Year 2024 Revenue: Cryo-Cell (CCEL) reported a revenue of $32 million for FY24, slightly up from $31.3 million the previous year, with Chairman David Portnoy noting impacts from investments related to the Duke License Agreement and anticipated higher legal expenses in FY25.
Investment Opportunities: TipRanks offers tools for investors to discover top-rated stocks and streamline their search for investment opportunities, highlighting strong buy ratings from analysts.
Cryo-Cell International Inc Reports Decrease in Q3 Profit
Earnings Decline: Cryo-Cell International Inc reported a decrease in earnings for the third quarter, with profits falling to $0.75 million ($0.09 per share) from $1.05 million ($0.13 per share) in the same period last year.
Revenue Drop: The company's revenue also declined by 3.0%, totaling $7.83 million compared to $8.07 million in the previous year.
Insider Buying Update for Friday, September 12: CCEL, AROW
Cryo-Cell International Insider Activity: Chairman and Co-CEO David Portnoy purchased 42,900 shares of CCEL at $4.43 each, totaling $189,986, and is currently up 6.1% based on recent trading highs.
Arrow Financial Insider Activity: CFO Penko Krassimir Ivanov bought 5,000 shares of AROW at $29.10 each for a total of $145,499, with previous investments totaling $391,248 at an average of $29.14 per share.
Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend
Dividend Announcement: Cryo-Cell International, Inc. has approved a reduced quarterly cash dividend of $0.15 per share due to the current economic environment, with payment expected on May 30, 2025.
Company Overview: Founded in 1989, Cryo-Cell is the first private cord blood bank and has provided services to over 500,000 parents globally, while also partnering with Duke University for public banking initiatives.
Maxim Group Maintains Buy on Cryo-Cell International, Lowers Price Target to $8.5
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
Financial Performance: Cryo-Cell International reported a revenue increase to $32.0 million for fiscal 2024, with a net income of $402,000, contrasting with a net loss of $9.5 million in the previous year due to significant impairments.
Company Overview and Future Outlook: Founded in 1989, Cryo-Cell is a leading private cord blood bank that has expanded its services and partnerships, including a collaboration with Duke University, while anticipating higher legal expenses in fiscal 2025.
Cryo-Cell reports FY24 EPS 5c vs ($1.14) last year
Fiscal Year 2024 Revenue: Cryo-Cell (CCEL) reported a revenue of $32 million for FY24, slightly up from $31.3 million the previous year, with Chairman David Portnoy noting impacts from investments related to the Duke License Agreement and anticipated higher legal expenses in FY25.
Investment Opportunities: TipRanks offers tools for investors to discover top-rated stocks and streamline their search for investment opportunities, highlighting strong buy ratings from analysts.
